Document:

EX-10.17.3

 Exhibit 10.17.3 

THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO SUCH SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED. 
 BIOCEPT, INC. 

WARRANT TO PURCHASE COMMON STOCK 
  

			
	No. CSW-10	  	July 31, 2013

 THIS CERTIFIES THAT, for
value received, Goodman Co. Ltd. or its assigns (collectively, the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from BIOCEPT,
INC., a Delaware corporation (the “Company”), up to such number of fully paid and nonassessable shares of Common Stock of the Company as set forth herein, during the Exercise Period (as
defined below). 
 1.      DEFINITIONS.   As
used herein, the following terms shall have the following respective meanings: 
 (a)    
“Exercise Period” shall mean the period commencing on the date of the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering
the offer and sale of the Company’s Common Stock for the account of the Company (the “IPO”) and ending two (2) years thereafter, unless sooner terminated as provided below. 

(b)       “Exercise Price” shall mean the per share
purchase price of the Company’s Common Stock sold in the IPO. 
 (c)      
“Exercise Shares” shall mean the Company’s Common Stock. 

2.      NUMBER OF SHARES.   The
number of Exercise Shares for up to which this Warrant may be exercisable is 333,333, subject to adjustment as provided in Section 6 below. 

3.      EXERCISE OF WARRANT.  
The rights represented by this Warrant may be exercised in whole or in part at any time during the Exercise Period, by delivery of the following to the Company at its address set forth on the signature page hereto (or at such other address as it may
designate by notice in writing to the Holder): 
 (a)       An executed Notice of
Exercise in the form attached hereto; 
 (b)       Payment of the Exercise Price
either (i) in cash or by check, (ii) by cancellation of indebtedness, or (iii) any combination thereof; and 

  
 1 

 (c)       This Warrant. 

Upon the exercise of the rights represented by this Warrant, a certificate or certificates for the Exercise Shares so
purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder within a reasonable time after the rights represented by this Warrant shall have been so
exercised. 
 The person in whose name any certificate or certificates for Exercise Shares are to be issued upon exercise of
this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date of delivery of such certificate or certificates,
except that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person shall be deemed to have become the holder of such shares at the close of business on the next succeeding date on
which the stock transfer books are open. 
 4.      REPRESENTATIONS OF
THE HOLDER. 
 4.1       Acquisition of Warrant for
Personal Account. The Holder represents and warrants that it is acquiring this Warrant and the Exercise Shares solely for its account for investment and not with a view to or for sale or distribution of said Warrant or Exercise Shares or any
part thereof. The Holder also represents that the entire legal and beneficial interests of this Warrant and Exercise Shares the Holder is acquiring is being acquired for, and will be held for, its account only. 

4.2       Information and Sophistication. Holder hereby: (i) acknowledges that it
has received all the information it has requested from the Company and it considers necessary or appropriate for deciding whether to acquire this Warrant and the Exercise Shares, (ii) represents that it has had an opportunity to ask questions
and receive answers from the Company regarding the financial condition of the Company and the risks associated with the acquisition of this Warrant and the Exercise Shares and (iii) further represents that it has such knowledge and experience
in financial and business matters that it is capable of evaluating the merits and risk of this investment. 

4.3       Ability to Bear Economic Risk. Holder acknowledges that investment in the
securities of the Company involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Exercise Shares for an indefinite period of time and to suffer a complete loss of its
investment. 
 4.4       Securities Are Not Registered. 

(a)       The Holder understands that this Warrant and the Exercise Shares have not been
registered under the Securities Act on the basis that no distribution or public offering of the stock of the Company is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding its representations,
the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the securities. The
Holder has no such present intention. 

  
 2 

 (b)       The Holder recognizes that this
Warrant and the Exercise Shares must be held indefinitely unless they are subsequently registered under the Securities Act or an exemption from such registration is available. The Holder recognizes that the Company has no obligation to register this
Warrant or the Exercise Shares, or to comply with any exemption from such registration. 

4.5       Disposition of Warrant and Exercise Shares. 

(a)       The Holder further agrees not to make any disposition of all or any part of
this Warrant or Exercise Shares in any event unless and until: 
 (i)       The
Company shall have received a letter secured by the Holder from the Securities and Exchange Commission stating that no action will be recommended to the Commission with respect to the proposed disposition; 

(ii)       There is then in effect a registration statement under the Securities Act
covering such proposed disposition and such disposition is made in accordance with said registration statement; or 

(iii)       The Holder shall have notified the Company of the proposed disposition and
shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, and if reasonably requested by the Company, the Holder shall have furnished the Company with an opinion of counsel, reasonably
satisfactory to the Company, for the Holder to the effect that such disposition will not require registration of this Warrant or Exercise Shares under the Securities Act or any applicable state securities laws. The Company agrees that it will not
require an opinion of counsel with respect to transactions under Rule 144 of the Securities Act, except in unusual circumstances. 

(b)       The Holder understands and agrees that all certificates evidencing the shares
to be issued to the Holder may bear the following legend: 
 THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER THE ACT OR AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED. 
 4.6       Accredited Investor
Status. The Holder is an accredited investor or is represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 

5.      COVENANTS OF THE COMPANY. 

5.1       Covenants as to Exercise Shares. The Company covenants and agrees that all Exercise Shares
that may be issued upon the exercise of the rights represented by this 

  
 3 

 
Warrant will, upon issuance, be validly issued and outstanding, fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Company further
covenants and agrees that the Company will at all times during the Exercise Period, have authorized and reserved, free from preemptive rights, a sufficient number of shares to provide for the exercise of the rights represented by this Warrant. If at
any time during the Exercise Period the number of authorized but unissued shares is not sufficient to permit exercise of this Warrant, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to increase its
authorized but unissued shares to such number of shares as shall be sufficient for such purposes. 

5.2       No Impairment.   Except and to the extent as waived or
consented to by the Holder, the Company will not, by amendment of its Amended and Restated Articles of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other
voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and
in the taking of all such action as may be necessary or appropriate in order to protect the exercise rights of the Holder against impairment. 

6.      ADJUSTMENT OF EXERCISE
PRICE.   In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations,
reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate
Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment; provided,
however, that such adjustment shall not be made with respect to, and this Warrant shall terminate if not exercised prior to, the events set forth in Section 8 below. The form of this Warrant need not be changed because of any adjustment in
the number of Exercise Shares subject to this Warrant. 
 7.     
FRACTIONAL SHARES.   No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon
exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company
shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 

8.      EARLY TERMINATION.   In the event of,
at any time during the Exercise Period, any capital reorganization, or any reclassification of the capital stock of the Company (other than a change in par value or from par value to no par value or no par value to par value or as a result of a
stock dividend or subdivision, split-up or combination of shares), or an Asset Transfer or Acquisition (as defined in the Company’s Amended and Restated Articles of Incorporation, as amended) (other than a merger solely to effect a
reincorporation of the Company into another state), the Company shall provide to the Holder 20 days advance written notice of such 

  
 4 

 
reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets, and this Warrant shall terminate unless exercised prior to the occurrence of
such reorganization, reclassification, consolidation, merger or sale or other disposition of the Company’s assets. 

9.      MARKET STAND-OFF
AGREEMENT.   Holder shall not sell, dispose of, transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale with
respect to, any Common Stock (or other securities) of the Company held by such Holder, for a period of time specified by the managing underwriter(s) not to exceed 180 days following the effective date of a registration statement of the Company filed
under the Securities Act in connection with the IPO (or such longer period, not to exceed 34 days after the expiration of the 180-day period, as the underwriters or the Company shall request in order to facilitate compliance with NASD Rule 2711 or
NYSE Member Rule 472 or any successor or similar rule or regulation). Holder agrees to execute and deliver such other agreements as may be reasonably requested by the Company and/or the managing underwriter(s) which are consistent with the foregoing
or which are necessary to give further effect thereto. In order to enforce the foregoing covenant, the Company may impose stop-transfer instructions with respect to such Common Stock (or other securities) until the end of such period. Each Holder
agrees that any transferee of Common Stock (or other securities) shall be bound by this Section 9. The underwriters of the Company’s stock are intended third party beneficiaries of this Section 9 and shall have the right, power and
authority to enforce the provisions hereof as though they were a party hereto. 
 10.
     NO SHAREHOLDER RIGHTS.   This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a shareholder of the Company.

 11.      TRANSFER OF
WARRANT.   Subject to applicable laws and the restrictions on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon
delivery of this Warrant and the form of assignment attached hereto to any transferee designated by Holder. The transferee shall sign an investment letter in form and substance satisfactory to the Company. 

12.      LOST, STOLEN, MUTILATED
OR DESTROYED WARRANT.   If this Warrant is lost, stolen, mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the
case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as the Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the
Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable by anyone. 

13.      NOTICES, ETC.   All notices required
or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not,
then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying next
day delivery, with written verification of receipt. All communications shall be sent to the Company and the Holder at the address set forth on the 

  
 5 

 
signature page hereto, or at such other address as the Company or Holder may designate by 10 days advance written notice to the other party hereto. 

14.      ACCEPTANCE.   Receipt of this Warrant by the Holder
shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 

15.      COUNTERPARTS.   This Warrant may be executed in
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

16.      GOVERNING LAW.   This Warrant shall be
governed by, and construed and enforced in accordance with, the laws of the State of California, applied to agreements between California residents, made to be performed entirely within the State of California, without giving effect to conflicts of
law principles. 
 17.       AMENDMENT;
WAIVER.   Any term of this Warrant may be amended or waived with the written consent of the Company and the Holder. 

IN WITNESS WHEREOF, the Company has caused this Warrant to
be executed by its duly authorized officer as of the date set forth above. 
 BIOCEPT, INC. 

 

			
	By:	 	 /s/ David F. Hale

 
			
		
	Name:	 	David F. Hale

 
			
		
	Title:	 	   Executive Chairman

 
			
		
	Address:	 	 5810 Nancy Ridge Drive
 San Diego,
California 92121

 Acknowledged and accepted: 
  

			
	GOODMAN CO. LTD.
		
	By:	 	/s/ Takehito Yogo

			
		
	Name:	 	Takehito Yogo

			
		
	Title:	 	President & CEO

			
		
	Address:	 	5F KDX 5-3, 4 Sakae, Naka-ku Nagoya, 460-0008 Japan

  
 6 

 NOTICE OF EXERCISE 

TO: BIOCEPT, INC. 

(1)       The undersigned hereby elects to purchase
             Exercise Shares of Biocept, Inc. (the “Company”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise
price in full, together with all applicable transfer taxes, if any. 
 (2)       Please
issue a certificate or certificates representing said Exercise Shares in the name of the undersigned or in such other name as is specified below: 
  

 
 (Name) 

 
  

 
  

(Address) 

(3)       The undersigned represents that (i) the aforesaid Exercise Shares are
being acquired for the account of the undersigned for investment and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or reselling such shares;
(ii) the undersigned is aware of the Company’s business affairs and financial condition and has acquired sufficient information about the Company to reach an informed and knowledgeable decision regarding its investment in the Company;
(iii) the undersigned is experienced in making investments of this type and has such knowledge and background in financial and business matters that the undersigned is capable of evaluating the merits and risks of this investment and protecting
the undersigned’s own interests; (iv) the undersigned understands that the Exercise Shares issuable upon exercise of this Warrant have not been registered under the Securities Act of 1933, as amended (the “Securities
Act”), by reason of a specific exemption from the registration provisions of the Securities Act, which exemption depends upon, among other things, the bona fide nature of the investment intent as expressed herein, and, because such
securities have not been registered under the Securities Act, they must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; (v) the undersigned is aware that the
aforesaid Exercise Shares may not be sold pursuant to Rule 144 adopted under the Securities Act unless certain conditions are met and until the undersigned has held the shares for the number of years prescribed by Rule 144, that among the conditions
for use of the Rule is the availability of current information to the public about the Company and the Company has not made such information available and has no present plans to do so; and (vi) the undersigned agrees not to make any
disposition of all or any part of the aforesaid Exercise Shares unless and until there is then in effect a registration statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with said
registration statement, or the undersigned has provided the Company with an opinion of counsel satisfactory to the Company, stating that such registration is not required. 
  

					
	(Date)	 		  	  
 (Signature)

			
		 		  	
		 		  	  
 (Print name)

  

 ASSIGNMENT FORM 

(To assign the foregoing Warrant, execute this form 

and supply required information. Do not use this 

form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Warrant and all rights
evidenced thereby are hereby assigned to 

Name:                         
                                         
                                         
                                         
                           

(Please Print) 

Address:                        
                                         
                                         
                                         
                        

(Please Print) 
 Dated:
            , 20     
 Holder’s 

Signature:                        
                                   

Holder’s 

Address:                        
                                   

NOTE: The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration
or enlargement or any change whatever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.18

 Exhibit 10.18 
 BIOCEPT, INC. 
 NOTE AND WARRANT PURCHASE AGREEMENT 

THIS NOTE AND WARRANT PURCHASE
AGREEMENT (this “Agreement”) is made and entered into as of February 1, 2011 (the “Effective Date”) by and among BIOCEPT,
INC., a California corporation (the “Company”) and the Investors listed on the Schedule of Investors attached hereto (each an “Investor and collectively, the
“Investors”). 
 RECITALS 

WHEREAS, in exchange for a series of loans in an aggregate amount equal to
$5,000,000 from the Investors, the Company will issue secured convertible promissory notes and a warrant to purchase shares of the Company’s Preferred Stock (the “Preferred Stock”) to the Investors. 

AGREEMENT 
 NOW THEREFORE, the parties to this Agreement, for good and valuable consideration, the receipt and sufficiency of which is acknowledged and agreed,
hereby agree as follows: 
 1.        LOAN AMOUNT;
ISSUANCE OF NOTES AND WARRANT. 

1.1        Loan Amount; Issuance of Notes.    Subject
to the terms of this Agreement, the Investors agree, jointly and severally, to lend to the Company at each Closing (as defined below) the amount set forth on the Schedule of Investors attached hereto (each, a “Loan Amount”
and collectively the “Total Loan Amount” or “Loan”) against the issuance and delivery by the Company of convertible promissory notes for such amounts, in substantially the form attached hereto as
Exhibit A (each, a “Note” and collectively, the “Notes”). 
 1.2        Issuance of Warrants.    Subject to the terms of this Agreement, the Investors participating in each Closing agree to purchase
from the Company, and the Company agrees to issue to such Investors, a Warrant in the form attached hereto as Exhibit B (the “Warrant”) to purchase the number of shares of Preferred Stock set forth in the Warrant
(the “Warrant Shares”). 

1.3        Security Interest.    The payment
obligations evidenced by the Notes shall be secured by a security interest as described in the Notes and pursuant to a Subordinated Security Agreement in the form attached hereto as Exhibit C (the “Security
Agreement”). 
 2.        CLOSINGS;
DELIVERY. 
 2.1        Initial
Closing.    The initial closing of the purchase and sale of the Notes (the “Initial Closing”) shall be held on the date hereof at the offices of Cooley LLP, 4401 Eastgate Mall, San Diego, California
92121, or at such other time and place as the Company and the Investors mutually agree. 

  
 1. 

    (a)        Deliveries by the
Company.    At the Initial Closing, the Company shall deliver (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto under the heading “Initial Closing Principal
Amount of Note”) (b) a duly executed Warrant to purchase the Warrant Shares, and (c) the duly executed Security Agreement. 
     (b)        Deliveries by Investors.    At the Initial Closing, the Investor participating in the Initial Closing
shall deliver to the Company funds, by check or wire transfer, in the amount set forth opposite such Investor’s name on the Schedule of Investors attached hereto under the heading “Initial Closing Principal Amount of Note.”

 2.2        Second Closing.    On
March 1, 2011, the second closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Second Closing Principal Amount of Note” on the Schedule of Investors
attached hereto (the “Second Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Second Closing, the Company shall deliver to each Investor participating in the Second Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Second Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Second Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Second Closing Principal Amount of Note.” 

2.3        Third Closing.    On April 1, 2011,
the third closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Third Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Third Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Third Closing, the Company shall deliver to each Investor participating in the Third Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Third Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Third Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Third Closing Principal Amount of Note.” 

2.4        Fourth Closing.    On May 2, 2011, the
fourth closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Fourth Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Fourth Closing”) shall take place. 

  
 2. 

    (a)        Deliveries by the
Company.    At the Fourth Closing, the Company shall deliver to each Investor participating in the Fourth Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Fourth Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Fourth Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Fourth Closing Principal Amount of Note.” 

2.5        Fifth Closing.    On June 1, 2011, the
fifth closing of the purchase and sale of the Notes in the principal amounts set forth opposite each Investor’s name under the heading “Fifth Closing Principal Amount of Note” on the Schedule of Investors attached hereto (the
“Fifth Closing” and each of the Fifth Closing, Fourth Closing, Third Closing, Second Closing and Initial Closing, a “Closing”) shall take place. 

    (a)        Deliveries by the
Company.    At the Fifth Closing, the Company shall deliver to each Investor participating in the Fifth Closing (a) a duly executed Note (in the principal amount set forth on the Schedule of Investors attached hereto
under the heading “Fifth Closing Principal Amount of Note”) and (b) a duly executed Warrant to purchase the Warrant Shares. 
     (b)        Deliveries by Investors.    At the Fifth Closing, the Investors shall, in the aggregate, deliver to
the Company funds, by check or wire transfer, in the amount set forth on the Schedule of Investors attached hereto under the heading “Fifth Closing Principal Amount of Note.” 

The issuance of the Notes and the Warrants to the Investors at each Closing, as applicable, shall be made on the terms
and conditions set forth in this Agreement, provided that (i) the representations and warranties of the Company set forth in Section 3 hereof shall speak as of the date of such Closing and (ii) the representations and warranties of
each Investor participating in such Closing set forth in Section 4 hereof shall speak as of the date of such Closing. 
  

	3.	 REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

 The Company hereby represents and warrants to each Investor, as of each Closing, as
applicable, as follows: 
 3.1        Organization and Standing;
Articles and Bylaws.    The Company is a corporation duly organized and validly existing under, and by virtue of, the laws of the State of California and is in good standing under such laws. The Company has the requisite
corporate power to own and operate its properties and assets, and to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified and is authorized to transact business and is in good standing as a
foreign corporation in each jurisdiction in which 

  
 3. 

 
the failure to so qualify would have a material adverse effect on its business, properties, or financial condition. 

3.2        Corporate Power.    The Company will have
at each Closing all requisite legal and corporate power to execute and deliver this Agreement and to carry out and perform its obligations under the terms of this Agreement. 

3.3        Authorization.    All corporate action on
the part of the Company, its directors and its shareholders necessary for the authorization, execution, delivery and performance of this Agreement, the Notes, the Warrant and the Security Agreement (collectively, the “Loan
Documents”) by the Company and the performance of the Company’s obligations hereunder and thereunder, including the issuance and delivery of the Notes and Warrant and the reservation of the equity securities issuable upon
conversion of the Notes and exercise of the Warrant (collectively, the “Conversion Shares” and, together with the Notes and the Warrants, the “Securities”) has been taken or will be taken prior to the
issuance of such Securities, as applicable. The Loan Documents, when executed and delivered by the Company, shall constitute valid and binding obligations of the Company enforceable against the Company in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, (b) as limited by general principles of equity that restrict the
availability of equitable remedies and (c) with respect to rights to indemnity, subject to federal and state securities laws. The Securities, when issued in compliance with the provisions of the Loan Documents, will be validly issued, fully
paid and nonassessable. The issuance of the Securities pursuant to the provisions of this Agreement will not violate any preemptive rights or rights of first refusal granted by the Company that will not be validly complied with or waived. The
Securities, when issued in compliance with the provisions of the Loan Documents, will be free of any liens or encumbrances, other than any liens or encumbrances created by or imposed upon the Investor through no action of the Company; provided,
however, that the Securities may be subject to restrictions on transfer under (i) that certain Investor Rights Agreement, by and among the Company and the other signatories thereto, dated August 4, 2010 (the “Investor Rights
Agreement”), (ii) the Company’s Bylaws and (iii) state and/or federal securities laws. 
 3.4        Governmental Consents.    All consents, approvals, orders, or authorizations of, or registrations, qualifications,
designations, declarations, or filings with, any governmental authority, required on the part of the Company in connection with the valid execution and delivery of the Loan Documents, the offer, sale or issuance of the Securities, or the
consummation of any other transaction contemplated hereby shall have been obtained and will be effective at the Initial Closing and at each subsequent Closing, except for notices required or permitted to be filed with certain state and federal
securities commissions, which notices will be filed on a timely basis. 

3.5        Offering.    Assuming the accuracy of the
representations and warranties of the Investor contained in Section 4 hereof, the offer, issue, and sale of the Notes and the Warrant are and will be exempt from the registration and prospectus delivery requirements of the Securities Act of
1933, as amended (the “Securities Act”), and have been registered or qualified (or are exempt from registration and qualification) under the registration, permit, or qualification requirements of all applicable state
securities laws. 

  
 4. 

	4.	 REPRESENTATIONS AND WARRANTIES OF THE INVESTOR.

 Each Investor hereby represents and warrants to the Company as of each Closing in which
such Investor participates, as applicable, as follows: 

4.1        Requisite Power and Authority.    The
Investor has all necessary power and authority to execute and deliver this Agreement and the Loan Documents and to carry out their provisions. All action on the Investor’s part required for the lawful execution and delivery of this Agreement
and the Loan Documents has been taken. Upon their execution and delivery, this Agreement and the Loan Documents will be valid and binding obligations of the Investor, enforceable against the Investor in accordance with their terms, except
(a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights, and (b) as limited by general principles of equity that restrict the
availability of equitable remedies. 
 4.2        Purchase for Own
Account.    The Investor represents that it is acquiring the Securities solely for its own account and beneficial interest for investment only, and not for sale or with a view to distribution of the Securities or any part
thereof, has no present intention of selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the same, and does not presently have reason to anticipate a change in such intention.

 4.3        Information and
Sophistication.    The Investor (i) acknowledges that it has received all the information that it or its qualified purchaser representative has requested from the Company and that it considers necessary or appropriate
for deciding whether to acquire the Securities, (ii) represents that it or its qualified purchaser representative has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of
the Securities and to obtain any additional information necessary to verify the accuracy of the information given the Investor and (iii) further represents that it has such knowledge and experience in financial and business matters that it is
capable of evaluating the merits and risk of this investment. Without limiting the foregoing, the Investor is relying on its own independent investigation of the Company and on its own respective professional advisors in entering into this Agreement
and consummating the transactions described herein. 

4.4        Ability to Bear Economic Risk.    The
Investor acknowledges that investment in the Securities involves a high degree of risk, and represents that it is able, without materially impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a
complete loss of its investment. 
 4.5        Further Limitations on
Disposition.    Without in any way limiting the representations set forth above, the Investor further agrees not to make any disposition of all or any portion of the Securities unless and until: 

    (a)        There is then in effect a registration
statement under the Securities Act covering such proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 5. 

 (b)        (i) The
transferee has agreed in writing to be bound by the terms of this Agreement, (ii) the Investor shall have notified the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances
surrounding the proposed disposition, and (iii) if reasonably requested by the Company, the Investor shall have furnished the Company with an opinion of counsel, reasonably satisfactory to the Company, that such disposition will not require
registration of such shares under the Securities Act. It is agreed that the Company will not require opinions of counsel for transactions made pursuant to Rule 144, except in unusual circumstances. The Company will not require the transferee to be
bound by the terms of this Agreement after the Company’s first firm commitment underwritten public offering of its Common Stock registered under the Securities Act (the “Initial Offering”). 

(c)        Notwithstanding the provisions of subsections (a) and
(b) above, no such restriction shall apply to a transfer by the Investor to an entity affiliated by common control (or other related entity) with the Investor (each such transferee, an “Affiliate” of the Investor);
provided that in each case the transferee will agree in writing to be subject to the terms of this Agreement to the same extent as if the transferee were an original Investor hereunder. 

(d)        Each certificate evidencing the Securities to be issued to the
Investor shall be stamped or otherwise imprinted with legends substantially similar to the following (in addition to any legend required under (i) the Investor Rights Agreement, (ii) the Company’s Bylaws and (iii) applicable
state securities laws): 
 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933 (THE “ACT”) AND MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, ASSIGNED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER THE ACT OR UNLESS THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
SATISFACTORY TO THE COMPANY AND ITS COUNSEL THAT SUCH REGISTRATION IS NOT REQUIRED. 
 THE
SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO THE TERMS AND CONDITIONS OF A CERTAIN NOTE AND WARRANT PURCHASE AGREEMENT BY AND BETWEEN THE INVESTOR AND THE COMPANY. COPIES OF SUCH AGREEMENT
MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY OF THE COMPANY. 

(e)        The Company shall be obligated to reissue promptly unlegended
certificates representing any Securities held by the Investor at the request of the Investor if the Company has completed its Initial Offering and the Investor has obtained an opinion of counsel (which counsel may be counsel to the Company)
reasonably acceptable to the Company to the effect that the securities proposed to be disposed of may lawfully be disposed of without registration, qualification and legend. 

  
 6. 

    (f)        Any legend endorsed on an instrument
pursuant to applicable state securities laws and the stop-transfer instructions with respect to such securities shall be removed upon receipt by the Company of an order of the appropriate state securities authority authorizing such removal.

 4.6        Accredited Investor
Status.    The Investor is an accredited investor or is represented by a purchaser representative within the meaning of Regulation D under the Securities Act. 
 5.        FURTHER ASSURANCES.    The Company and each Investor agree and covenant that at any time and from
time to time it will promptly execute and deliver to each other such further instruments and documents and take such further action as each of the parties hereto may reasonably require in order to carry out the full intent and purpose of this
Agreement. 
  

	6.	 MISCELLANEOUS. 

 6.1        Binding Agreement.    The terms and conditions of this Agreement shall inure to the benefit of and be binding upon the
respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any third party any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly
provided in this Agreement. 
 6.2        Governing
Law.    This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents, made and to be performed entirely within the State of California without
giving effect to its conflicts of laws principles. 

6.3        Counterparts; Facsimile.    This Agreement
may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Facsimile signatures shall be as effective as original signatures. 

6.4        Expenses.    Each party shall pay all costs
and expenses that it incurs with respect to the negotiation, execution, delivery and performance of this Agreement and the transactions contemplated hereby. 
 6.5        Titles and Subtitles.    The titles and subtitles used in this Agreement are used for convenience only and are not to be
considered in construing or interpreting this Agreement. 

6.6        Notices.    All notices required or
permitted hereunder or under the Notes or the Warrant shall be in writing (including facsimile, electronic mail or similar electronic transmissions), and shall be deemed effectively given: (a) when received by the addressee, if delivered by
hand, facsimile, electronic mail or similar form of electronic transmission, (b) five days after mailing, if mailed by registered or certified mail, return receipt requested, postage prepaid or (c) one day after deposit with a nationally
recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent (i) to the Company at 5810 Nancy Ridge Drive, San Diego, California 92121, Attn: Meg McGilley, Facsimile No:
(858) 320-8261 or (ii) to the Investors at the address shown on the Schedule of 

  
 7. 

 
Investors, or at such other address as such party may designate by written notice to the other party. 
 6.7        Amendment; Waiver.    Except as otherwise set forth herein, no amendment or waiver of any provision of this Agreement shall be
effective unless in writing and approved by the Company and the holders of at least a majority in interest of the outstanding Securities. 
 6.8        Expenses.    Each party shall pay all costs and expenses that it incurs with respect to the negotiation, execution, delivery
and performance of this Agreement. 
 6.9        Delays or
Omissions.    It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach, default or noncompliance by another party under this Agreement, the Notes or the Warrant,
shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence therein, or of or in any similar breach, default or noncompliance thereafter occurring. It is
further agreed that any waiver, permit, consent or approval of any kind or character on any party’s part of any breach, default or noncompliance under this Agreement, the Notes or the Warrant, or any waiver on such party’s part of any
provisions or conditions of this Agreement, the Notes or the Warrant must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies under this Agreement, the Notes or the Warrant, by law, or
otherwise afforded to any party, shall be cumulative and not alternative. 

6.10        Entire Agreement.    This Agreement and
the exhibits hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any representations, warranties, covenants and
agreements except as specifically set forth herein. 

6.11        California Corporate Securities
Law.    THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT
OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION OR IN THE ABSENCE OF AN EXEMPTION FROM SUCH QUALIFICATION IS UNLAWFUL. PRIOR TO ACCEPTANCE OF SUCH CONSIDERATION BY THE COMPANY, THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE
EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED OR AN EXEMPTION FROM SUCH QUALIFICATION BEING AVAILABLE. 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK] 

  
 8. 

 IN WITNESS WHEREOF, the
parties have executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	 COMPANY:
  

BIOCEPT, INC.,
 a California corporation

		
	By:	 	/s/ Faye Wilson
		 	 Faye Wilson
 Lead
Director

  
  
  

 
  
  

 
  

[SIGNATURE PAGE TO NOTE AND WARRANT
PURCHASE AGREEMENT] 

 IN WITNESS WHEREOF, the parties have
executed this NOTE AND WARRANT PURCHASE AGREEMENT as of the date first written above. 

 

			
	 THE REISS FAMILY GST EX MARITAL

DEDUCTION TRUST UDT 12/19/1988:

		
	By: 	 	/s/ Claire K.T. Reiss

 
			
		
	Name: 	 	Claire K.T. Reiss

 
			
		
	Title: 	 	Trustee

  

			
	 THE REISS FAMILY SURVIVOR’S
TRUST
 UDT DATED DECEMBER 19, 1988:

		
	By: 	 	/s/ Claire K.T. Reiss

 
			
		
	Name: 	 	Claire K.T. Reiss

 
			
		
	Title: 	 	Trustee

  
  
  

 
  
  

 
  

[SIGNATURE PAGE TO NOTE AND WARRANT
PURCHASE AGREEMENT] 

 SCHEDULE OF INVESTORS 

 

											
	 INVESTOR NAME
	 	INITIAL CLOSING
PRINCIPAL
AMOUNT 
OF NOTE	 	SECOND CLOSING
PRINCIPAL
AMOUNT 
OF NOTE	 	THIRD CLOSING
PRINCIPAL
AMOUNT 
OF
NOTE	 	FOURTH 
CLOSING
PRINCIPAL
AMOUNT OF NOTE	 	FIFTH CLOSING
PRINCIPAL
AMOUNT 
OF NOTE
						
	 The Reiss Family GST

Exempt Marital Deduction

Trust
	 	$1,000,000	 	To be determined	 	To be determined	 	To be determined	 	To be determined
						
	 Address:
 9675 La Jolla Farms
Road
 La Jolla, CA 92037
	 		 		 		 		 	
						
	 The Reiss Family

Survivor’s Trust UDT
 dated
December 19, 1988
	 	$0	 	To be determined	 	To be determined	 	To be determined	 	To be determined
						
	 Address:

9675 La Jolla Farms Road
 La
Jolla, CA 92037
	 	$0	 	To be determined	 	To be determined	 	To be determined	 	To be determined
		 	  

	 TOTAL:
	 	$1,000,000	 	$1,000,0001	 	$1,000,0001	 	$1,000,0001	 	$1,000,0001

  
  
  

 
  
  

 
 1 $1,000,000 in the aggregate to be lent by The Reiss Family GST Exempt
Marital Deduction Trust and/or The Reiss Family Survivor’s Trust UDT dated December 19, 1988. 

 EXHIBIT A 

FORM OF SECURED CONVERTIBLE PROMISSORY NOTE 

 EXHIBIT B 

FORM OF WARRANT 

 EXHIBIT C 

FORM OF SECURITY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]